P-295 Efficacy, survival and safety of selinexor, bortezomib and dexamethasone (SVd) in patients with lenalidomide-refractory multiple myeloma: subgroup data from the BOSTON trial — María‐Victoria Mateos (2023) | RDL Network
P-295 Efficacy, survival and safety of selinexor, bortezomib and dexamethasone (SVd) in patients with lenalidomide-refractory multiple myeloma: subgroup data from the BOSTON trial
María‐Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella, Holger W. Auner, Michèle Cavo, Meletios A Dimopoulos, Martina Bianco, G Merlo, Charles la Porte, Philippe Moreau
Joshua Richter, Jacob P. Laubach, Steve Stricker, Fredrik Schjesvold, David Cohan, Anna Sureda, Ewa Lech‐Marańda, Meral Beksaç, Vânia Hungria, Meletios A Dimopoulos, Ajai Chari, Paul G. Richardson, Philippe Moreau
María‐Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella, Michèle Cavo, Meletios A Dimopoulos, Martina Bianco, G Merlo, Charles la Porte, Paul G. Richardson, Philippe Moreau
María‐Victoria Mateos, Monika Engelhardt, Xavier Leleu, Mercedes Gironella, Michèle Cavo, Meletios A Dimopoulos, Martina Bianco, G Merlo, Charles la Porte, Philippe Moreau
Thierry Façon, Holger W. Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Špıčka, Luděk Pour, Meletios A Dimopoulos, Iryna Kriachok, Halyna Pylypenko, Xavier Leleu, Hang Quach, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Mamta Garg, Don A. Stevens, Jatin J. Shah, Paul G. Richardson, Sebastian Grosicki
Discussion(0)
No comments yet. Be the first to comment.